Armata Pharmaceuticals, Inc.
AMEXArmata Pharmaceuticals reports today against a rough backdrop: the stock has shed 21% over the past month and slipped another 2.6% on the week to $8.82, even as the broader small-cap biotech universe found its footing. Peers like CRBU and CBIO both gained more than 8% on the week — making ARMP's underperformance the clearest signal heading into the…
ARMP short interest dips 26.7% over one week to 0.68% of float, while stock slides 31.2% in same period.
Snapshot as of 22 Jun 2026
Armata Pharmaceuticals reports today against a rough backdrop: the stock has shed 21% over the past month and slipped another 2.6% on the week to $8.82, even as the broader small-cap biotech universe found its footing.…
Armata Pharmaceuticals filed Q1 results after the close on May 13, and the headline EPS of -$3.16 missed the -$0.38 consensus by a wide margin. Revenue of $789K came in ahead of the prior year's $491K, but the earnings…
Armata Pharmaceuticals climbed 12% this week to $12.92, capping a 57% month-long run. Short interest rose 17% over thirty days to 337k shares. Analysts hold a $17.50 target. CEO and CFO sold shares in mid-March near…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ARMP — free to start on ORTEX.
Sign up for free →Open ARMP on ORTEX